AIDSmeds.com - IAC 2008 : Future Options for the Treatment Experienced

	Kaletra to Norvir/Reyataz Switch Improves Fat, Glucose Metabolism	done null
	Higher HIV Levels Increase Lymphoma Risk	done null
	Tesamorelin for Lipodystrophy Approval Application Filed	done null
	Crystal Use Might Increase Lymphoma Risk	done null
	New Hope for HIV Eradication	done null
	Apricitabine Trial Continues, With Changes	done null
	Liver Transplant in HBV/HIV Coinfected Patients Successful	done null
	Repeat Pregnancies Likely With Only Condoms	done null
	Enzyme Related to Heart Disease No Higher in HIV-Positive Women	done null
	Early HIV Treatment Could Protect Against Brain Dysfunction	done null
	B Cell Test Predicts Who Will Get Meningitis	done null
	HIVMA Advocates for Public Insurance Option	done null
	Interleukin-10 Blunts HIV Infection and Disease Progression	done null
	Preterm Delivery, Low Birth Weight Unlikely with Perinatal HIV Treatment	done null
	New Ideas About Reaching HIV Sanctuaries in the Body	done null
	HIV Infection and Diabetes Risk	done null
	Second-Line Treatment for PCP a Viable Alternative	done null
	Improving Survival From Non-Hodgkin’s Lymphoma	done null
	High Percentage of U.S. Residents Receiving Late HIV Diagnoses	done null
	HIV and ARV Therapy Accelerate Bone Loss	done null

May 2009

Success

null

	Turning On Old Genes to Prevent HIV	done null
	HPV Greatly Increases HIV Infection in MSM	done null
	Lower-Dose ARVs to Be Tested in New Gates-Funded Program	done null
	Obama to Broaden, Expand PEPFAR to $51 Billion Over Six Years	done null
	Hep C and Heavy Drinking Tied to Bone Fractures	done null
	Telaprevir Increases Hep C Treatment Response	done null
	Journalist Files Libel Suit Against HIV Treatment Advocate	done null
	HPV Vaccine Is Active in MSM	done null
	Gardasil Blocks About Half of Cervical Lesions	done null
	Study: HIV Not Becoming More Virulent	done null
	Interleukin-21 Tied to Control of Chronic Infections Like HIV	done null
	HIV Associated With Marked Declines in Lung Function	done null
	Study Authors Say Treat HIV and OIs at Same Time	done null
	Is HIV Itself a Risk Factor for Heart Disease?	done null
	Frequent False-Positive Drug Tests With Efavirenz Users	done null
	Gingko May Lower Efavirenz Blood Levels	done null
	Combivir Linked to Lipoatrophy in Small European Study	done null
	New California Budget Slashes $55.5 Million From AIDS Funds	done null
	Kaletra Maintenance Monotherapy Holds Up Over 96 Weeks	done null
	Viral Load Tied to Kidney Function	done null
	Is Marijuana as Effective as OTC and Prescription Drugs?	done null

April 2009

Success

null

	New Drug May Boost HIV Treatment Effectiveness	done null
	Published Study Says Start HIV Treatment as Early as Possible	done null
	Shorter Duration Hep C Treatment May Be Possible for Some	done null
	Vitamin D Might Blunt Tenofovir-Associated Bone Problems	done null
	HIV Treatment Alone Is Enough for Most Who Catch KS Early	done null
	Kaletra Might Cause Heart Rhythm Disturbances	done null
	Leptin Reduces Belly Fat	done null
	Scientists Discover How Herpes Viruses May Lead to Cancer	done null
	Another Study Recommends Earlier ARV Treatment	done null
	Is Big Pharma Stifling AIDS Research?	done null
	Possible Interaction Between Isentress and Intelence?	done null
	GSK, Pfizer Team for Combined HIV Drug Company	done null
	BMS Launches Co-Pay Assistance Program	done null
	“Quad” HIV Pill Enters Phase II Study	done null
	Isentress’s Prevention Potential	done null
	HIV Treatment May Offer Only Partial Heart Protection	done null
	New Research Shows Why Antibodies Fail to Control HIV	done null
	Atripla Co-pay Program Announced	done null
	HIV Positive and Negative Have Equal Liver Transplant Survival Rates	done null
	Aquamid a Safe and Effective Treatment for Facial Wasting	done null
	Prezista Levels in the Brain High Enough to Control HIV	done null
	CDC Issues H1N1 (Swine Flu) Guidance for People With HIV	done null
	GSK Studies Show No Increased Heart Attack Risk From Abacavir	done null

March 2009

Success

null

	Some HIV Drugs May Cause Pulmonary Hypertension	done null
	Study: Reyataz Negatively Affects Blood Vessel Function	done null
	Methadone and Protease Inhibitor Interaction Called Into Question	done null
	HIV and Women	done null
	Drug Levels in Hair Predict Treatment Success	done null
	Call for a Coordinated Cure Effort	done null
	Africans and African Americans May Progress to AIDS More Slowly	done null
	Noninvasive Hep C Test Nearly as Good as a Biopsy	done null
	Antiretrovirals Reduce AIDS Deaths, But Some Illnesses Remain Serious	done null
	Low-Dose Efavirenz Safe for Some	done null
	Big Leap Forward in HIV Vaccine Science	done null
	Older Age Linked to Less Depression	done null
	Lymphoma Drug Wakes Up Dormant HIV	done null
	HPV Infection Rates High in HIV-Positive MSM	done null
	Apricitabine Efficacy, Safety Hold Up Over 96 Weeks	done null
	Kidney Tube Dysfunction in Tenofovir Users	done null
	More Help for Uninsured Patients	done null
	Treatment Adherence: Still Important	done null
	Neurocognitive Disorders, Poor Adherence in Older HIV-Positive Adults	done null
	CD4 Cells Also Increase in HIV, Hep C Coinfection	done null
	Innovative Video Captures Cell-to-Cell HIV Transfer	done null
	One in Five HIV-Positive Women Drinks Heavily	done null
	Most South Carolina HIV Patients Not in Care	done null

February 2009

Success

null

	Tenofovir Kidney Toxicity in HIV-Positive Teens	done null
	New HIV Gene Therapy Starts Human Studies	done null
	Therapeutic Drug Monitoring May Benefit People of Color	done null
	Shortage in HIV Providers Could Be Looming	done null
	Isentress Gets Full FDA Approval for Experienced Patients	done null
	Diabetes Drug Avandia Helps Reverse Lipoatrophy	done null
	GS 9350 and SPI-452: Emerging Alternatives to Norvir Boosting	done null
	HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmission	done null
	Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Risk	done null
	Start HIV Treatment Early—But When?	done null
	IL-2 Fails in Two Large Studies	done null
	Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIV	done null
	PIs, Abacavir and Cardiovascular Disease: What’s the Risk?	done null
	D:A:D Study: Reduce Modifiable Risk Factors to Improve Survival	done null
	HIV Itself Is a Major Heart Disease Risk Factor	done null
	Isentress Shows Long-Term Benefits in Treatment-Experienced Patients	done null
	First Data From Injectable PRO 140 Study	done null
	Antidepressants Improve Viral Load Response to Treatment Due to Better Adherence	done null
	Microbicides Make a Comeback	done null
	Smoking Cessation: Hispanics, Nicotine Patch Users Do Best	done null
	Nerve Damage Is a Common Problem in People With HIV	done null
	HDL and Small HDL Particles Predict Cardio Problems in HIV	done null
	Scientists Still Seeking Clues to Abacavir Heart Attack Mystery	done null
	Quarter of U.S. Positive Women Not Receiving Annual Pap Smears	done null
	Aging and HIV a Destructive Combination on the Brain	done null
	Psoriasis Drug Possibly Linked to Brain Infection	done null
	Antiretroviral Highlights from CROI	done null
	Testosterone Therapy: Good for Women Too	done null
	Lymphoma: Death Rates Still High, but Cancer May Be Predicted	done null
	Sexually Transmitted Hepatitis C in MSM in the U.S. and Europe	done null
	Peanut Recall, Salmonella Risk: Important HIV Information	done null
	Half of Deaths in People With HIV No Longer From AIDS	done null
	Being Female Linked to Poorer Survival	done null
	Two Rare Skin Cancers More Common in People With AIDS	done null
	HIV and Cancer: Prevalence and Prevention	done null
	HIV and the Brain: What to Watch Out For	done null
	First HIV Gene Therapy Proves Safe With Hint of Effectiveness	done null
	Prevention Highlights, Part 1: PrEP	done null
	Treating HIV and Cancer With Radioimmunotherapy	done null
	Prevention Highlights, Part 2: Treatment as Prevention	done null

January 2009

Success

null

	Up Kaletra Dose During Late Pregnancy	done null
	Not Enough Antibodies to Protect Against Superinfection	done null
	Starting HIV Treatment Early Restores Immune Cells to Normal Levels	done null
	Missed Doctors Appointments Bad for Survival	done null
	IL-2 Doesn’t Increase Lymphoma Risk	done null
	Premature Aging of CD4 Cells Linked to Faster Disease Progression	done null
	Gilead Developing New Four-in-One HIV Drug	done null
	Blood Type Discovery May Lead to New Tools in HIV Fight	done null
	Poor Viral Control With Once-Daily Viramune, Viread and Epivir	done null
	Prezista’s Potency Enhanced by 2 HIV Mutations	done null
	Project Inform Founder Martin Delaney Honored for AIDS Work	done null
	Kidney and Patient Survival Rates High in Positive Transplant Recipients	done null
	Myriad Acquires Rights to Develop Bevirimat	done null
	No Evidence of Superinfection Between Long-Term Partners	done null
	Marty Delaney, Founder of Project Inform, Dies	done null
	Earlier HIV Treatment Protects Against Hep C Liver Damage	done null
	HIV Treatment Boosts Lung Cancer Survival in People With HIV	done null
	New Heat-Stable Norvir Tablet Sent to FDA for Approval	done null
	Non-AIDS Cancers on the Rise	done null
	Once-Daily Better Than Twice-Daily HIV Treatment	done null

December 2008

Success

null

	Latinos Most Likely, Blacks Least Likely to Have Lipodystrophy	done null
	Proteins That Contain Selenium Reduce HIV Reproduction	done null
	Abacavir May Not Significantly Increase Inflammatory Proteins	done null
	Prostate Cancer Treatment Works Well in HIV-Positive Men	done null
	Zoledronate Effectively Treats HIV-Related Bone Mineral Loss	done null
	HIV-Positive Women More Likely to Have Precancerous Anal Lesions	done null
	Antibody Test Not the Best for Diagnosing Acute Hep C	done null
	HPV Vaccine for Guys: Positive Early Data	done null
	Blocking CD8 Cell Receptor Prolongs Survival in Monkeys	done null
	Obesity Common in HIV-Positive Patients	done null
	Treatment Adherence: Better Is Best	done null
	Tesamorelin Diminished Gut Fat in Phase 3 Study	done null
	Thyroid Problems More Common in HIV Population	done null
	High Rates of Metabolic Syndrome, Cardio Risk in Older People With HIV	done null
	Truvada, Viread and Emtriva Co-Pay Assistance Program Now Available	done null
	Ziagen, Prezista Tablets Now Available for Children	done null
	A Test to Predict Responses to Hep C Treatment?	done null
	Does Smoking Reduce Kaposi’s Sarcoma Risk?	done null
	Generic Zerit Approved in United States	done null
	Circumcision Prevents HIV Infection in U.S. Heterosexual Men	done null

November 2008

Success

null

	Major Updates to DHHS HIV Treatment Guidelines	done null
	Truvada vs. Epzicom: The Debate Goes On	done null
	Drug-Resistant Staph: Growing Concern Among People With HIV	done null
	High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Study	done null
	Drug-Resistant Staph and HIV - Part 1	done null
	Drug-Resistant Staph and HIV - Part 2	done null
	HIV News at ICAAC/IDSA - Part 1	done null
	HIV News at ICAAC/IDSA - Part 2	done null
	Less Monitoring for Those Responding Well to Treatment?	done null
	Stopping Treatment More Hazardous for People With Hep and HIV	done null
	Astragalus Extract May Strengthen Immune Response to HIV	done null
	HIV Can’t Hide From Specially Engineered CD8 Cells	done null
	New GSK Program Reduces Out-of-Pocket Costs for HIV Meds	done null
	Lipoatrophy Associated With Weakening Hips	done null
	Treatment Interruptions May Still Have a Future	done null
	Small Study Fingers 'Silent' Heart Disease in HIV-Positive Men	done null
	Second-line Treatment Fails Twice as Often as First-line	done null
	Shutting Down an HIV Protein May Lead to Brain-Protecting Drugs	done null
	Cancer Risk Doubled in People With HIV	done null
	Once-Daily Intelence Could Work as First-line Treatment	done null
	Risks Remain for Late Treatment Takers	done null
	Bavituximab: A New Strategy for Fighting Viruses	done null
	Rates of Drug-Resistant Staph Increasing in People With HIV	done null
	Selzentry Receives Full FDA Approval	done null

October 2008

Success

null

	Delayed-Release Videx (EC) Now OK for Some Kids	done null
	FDA Approves Boosted-Reyataz for Treatment First-Timers	done null
	Tenofovir Linked to Mild Decrease in Kidney Function, but Not Kidney Disease	done null
	Pneumonia Hospitalizations Still High for Positive Patients	done null
	Low CD4s in People With Hepatitis and HIV Associated with Liver Cancer	done null
	Merck Testing Once-Daily Isentress	done null
	Strength Training Burns More Fat Than Endurance Exercise in HIV	done null
	Single Dose of Diflucan Good for Thrush	done null
	New Anti-HIV Drug Target Discovered	done null
	Menopause, Tenofovir and Didanosine Increase Bone Loss	done null
	Third Dose of Hep A Vaccine May Increase Immunity	done null
	Treatment Interruption After an Early Start Produced Steep CD4 Declines	done null
	50% of MRSA Skin Infections Return Within 1 Year	done null
	Norvir and Viral Hepatitis Increase HIV Drug levels, Risk of Side Effects	done null
	SMART Study: Viral Loads and Inflammation Explain Increased Cardio Risk	done null
	Prezista Approved for First-Time Treatment Takers	done null
	'Undetectable = Noninfectious' Debate Continues at U.K. Conference	done null
	Blood Clots More Common in People With Advanced HIV Disease	done null
	Isentress Comparable to Sustiva for First-Time Treatment	done null
	Selzentry Reanalysis Shows Potential as First-Line Treatment	done null
	Should ARV Treatment Be Started When CD4s Fall Below 500?	done null
	PRO 140 Has Long-Lasting Activity Against HIV	done null
	Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeks	done null
	New NNRTI Called RDEA806 Shows Promise	done null
	Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapy	done null
	OraSure Seeking FDA Approval for Rapid Hep C Test	done null
	EMD Serono Buys Rights to Sell Tesamorelin in U.S.	done null
	Has HIV Evolved to Become More Dangerous?	done null
	Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studies	done null

September 2008

Success

null

	Norvir and Heart Conduction Disturbances	done null
	Worsening Depression in Four Patients on Isentress	done null
	Vistide Not Effective in Treating PML	done null
	Genes, Not Race, Should Guide Antiretroviral Treatment	done null
	PAD Common in HIV-Positive Patients Over 50	done null
	Researchers Link Gene to Key Antibody Responses	done null
	High Rate of Circumcision Side Effects in Kenyan Survey	done null
	Further Possible Benefits of PrEP	done null
	HIV Status Unknown for Most “Negative” Men Online	done null
	People Now Able to Stay on First Antiretroviral Regimens Longer	done null
	HIV Stigma Hinders Access to Care and Prevention	done null
	Acyclovir Also Fights HIV in People With Herpes	done null
	Birth Defect Screening Just as Reliable in Positive Pregnant Women	done null
	Chamomile May Help Prevent Diabetes and Its Complications	done null
	New Maturation Inhibitor Enters Phase 2 Testing	done null
	Why Some Primates Aren’t Vulnerable to SIV	done null
	Relocation of Gut Bacteria Linked to Low CD4s	done null
	Twice-Daily Retrovir Now OK for Kids	done null
	Nipple Shield Filters HIV From Breast Milk	done null
	HIV Treatment Diminishes Non-AIDS Illnesses	done null
	Tropism Testing May Help Predict Disease Progression	done null
	Zetia Reduces LDL in People Living With HIV	done null
	Anti-Obesity Meds May Also Have Anti-HIV Benefits	done null
	Once-Daily Prezista as Good as Twice-Daily Dose for Some	done null

August 2008

Success

null

	Discrimination Doesn’t Worsen Treatment Adherence	done null
	Annual HIV Infections in U.S. Substantially Higher Than Believed	done null
	Human Growth Hormone May Reduce Internal Fatty Deposits	done null
	Similar Survival Among IDUs on ARV Treatment	done null
	Shortage of Health Care Workers Threatens African HIV Care	done null
	IAC Panelists: Scale Up, Leadership and Youth Crucial to HIV Response	done null
	Report: Now Is Time to Prepare for PrEP	done null
	Some Gender and Racial Differences with Three Protease Inhibitors	done null
	Isentress Continues to Show Well Versus Sustiva as First-Line Treatment	done null
	Hep C: The Other Epidemic	done null
	Stigma, Fear of Side Effects, Keep Many off Treatment	done null
	Sustiva Bests Kaletra for Treatment of Advanced HIV Disease	done null
	NNRTI Rilpivirine (TMC-278) Comparable to Sustiva in 96-Week Study	done null
	Abacavir and Heart Attack Risk: Round 2	done null
	Microbicides: Assessing Progress	done null
	Having Children a Priority for Many Positive Women	done null
	Achieving Universal Treatment Access: The Experience in Rural Malawi	done null
	New NNRTI RDEA806 Shows Promise in Seven-Day Study	done null
	Abacavir and Cardiovascular Risk: Is There or Isn’t There?	done null
	IDX899 Safe, Reduces Viral Load in Preliminary Study	done null
	Future Options for the Treatment Experienced	done null
	Isentress, Intelence and Prezista Combo Shines for Treatment Veterans	done null
	Studies Disagree on Abacavir for Patients With High Viral Loads	done null
	New Options for Those New to Treatment	done null
	Encouraging Data From Second Tesamorelin Study for Lipo	done null
	Viread Receives Second Approval for Hep B Infection	done null
	New HIV Numbers: New Prevention Strategy? Part 1	done null
	New HIV Numbers: New Prevention Strategy? Part 2	done null
	Defining the Risk Factors for Kidney Damage in Patients Using Tenofovir	done null
	Milk Thistle Shows Potential for Hep C	done null
	Human Rights Struggles Define AIDS Fight	done null
	Norvir Tablets Similar to Capsules, Expected in 2009	done null
	PrEP: Preparing For Success?	done null
	Antiretrovirals Diminish Artery Hardening	done null
	Vaccines: Lessons Learned	done null
	AIDS Activism For The Next Decade	done null
	Suicidal Thoughts Common in People With HIV	done null
	Rapid Hep C Disease Progression in HIV-Positive Men	done null
	Short-term Therapy May Help HIV-Related Depression	done null
	New Drug Interaction Information With Reyataz	done null
	Non-Nukes and Triglyceride Levels Affect HDL Cholesterol	done null
	Cases of HIV Detectable in Semen, but Not Blood	done null
	Better HIV Treatment Response Seen in Older Patients	done null
	PML Still a Risk and Often Progressive	done null
	Hormonal Contraceptives and HIV Disease Progression	done null
	SMART Study Findings on Abacavir and Cardiovascular Risk	done null

July 2008

Success

null

	Montaner: Treat HIV to Help Curb Infection Spread	done null
	CD4 Recovery Increases Asthma Risk in Children	done null
	Bone Fractures More Common in HIV	done null
	Same Mortality Rates for Negative and Positive People 5 Years After Infection	done null
	Guidelines Reiterate Resistance Testing for All New HIV Cases	done null
	Viramune Prescribing Information Updated	done null
	Fatty Liver Common in Patients With Metabolic Problems	done null
	HIV Can Take Shortcuts to Reproduce	done null
	Roche Abandoning In-House HIV Research	done null
	Therapeutic Vaccine Tanks in Study	done null
	Blood Tests Could Replace Liver Biopsies for Hep C	done null
	Progressive Resistance Exercise Good for People With HIV	done null
	Scientists Discover and Target HIV’s Weak Spot	done null
	Age Affects Response to Antiretroviral Therapy	done null
	Genetics May Make Africans More Vulnerable to HIV	done null
	Blood Test Predicts Hep C Treatment Response	done null
	Senate Reauthorizes PEPFAR	done null
	Anal Cancer Rates Higher in HIV-Positive Men	done null
	Overactive Immune Systems May Cause the Blues	done null
	Mediterranean and Low-Carb Better than Low-Fat Diets	done null
	Gilead’s Elvitegravir Enters Phase III Studies	done null
	Allergy Testing, Heart Risk Assessment Recommended Before Starting Abacavir	done null
	NRTIs Important as Component of Antiretroviral Therapy	done null
	Kaletra and Efavirenz Affect Prednisolone Levels	done null
	Life Expectancy With HIV Increases Dramatically	done null
	Meditation May Benefit the Immune System	done null
	Deaths From Cancer, Liver and Cardiovascular Disease Growing	done null
	Efavirenz Doesn’t Worsen Hep C Treatment Side Effects	done null

June 2008

Success

null

	Scientists Identify New HIV-Fighting Protein	done null
	Viracept Impurity Was Not at Cancer-Causing Levels	done null
	Scientists Record HIV Particle Being Born	done null
	African HIV Breast Feeding Studies Show Benefits	done null
	A New Improved HIV Tropism Test	done null
	Syphilis Treatment Response Improves With HIV Therapy	done null
	Mediterranean Diet May Lower Diabetes Risk	done null
	Combining Invirase and Garlic Capsules Not Recommended	done null
	Neuropathy Skin Patch Reduces Pain	done null
	Coinfection With HIV and HCV in Pregnancy	done null
	Scoring Tool Helps Predict KS Worsening	done null
	Experimental HIV Drug Hits Snag	done null
	Epilepsy Drug Doesn’t Reduce HIV Reservoir	done null
	Tibotec Launches Medication Reminder Service	done null
	Confirmation of Tesamorelin’s Lipo-Fighting Potential	done null
	Crack Is Wack in Women’s HIV Study	done null
	HIV Hospitalizations Halved Since 1994	done null
	Experts Recommend Heart Disease Screening in HIV	done null
	Cheaper Test for Atherosclerosis Works in HIV	done null
	Reyataz Approved for First-Line Use in Europe	done null
	Deep Vein Clotting Risk Higher in HIV	done null
	Zinc Fingers to the Fore	done null

May 2008

Success

null

	Rate of Heart Attacks Stable Despite Increased Risk	done null
	“Video Doctor” Reduces Unsafe Sex and Drug Use	done null
	Stimulated Cells Control SIV, and Hopefully HIV	done null
	Experimental HCV Treatment Shows Real Promise	done null
	New Report: Some ADAPs Cover HCV Treatment	done null
	Majority of Patients Will Be Able to Use Intelence	done null
	Antiretrovirals Vital in Treating Cancer	done null
	Higher-Dose Kaletra Plus Rifampicin Creates Liver Toxicity	done null
	Bone Marrow Deficits May Explain Blunted CD4 Response	done null
	Spying on an HIV Enzyme	done null
	Can Antidepressants Also Boost the Immune System?	done null
	GSK Hasn’t Mentioned Heart Attacks Reported in 2005 Letter	done null
	High Cholesterol Good for Hepatitis C Treatment?	done null
	Immune Cells Harbor Infectious Virus	done null
	New Developments in Abbott’s Norvir Court Case	done null
	GSK Responds to Accusations About Abacavir	done null
	Viracept OK Again for Children, Pregnant Women	done null
	New HIV Drug Discovery	done null
	Lingering Side Effects Reported With Facial Filler	done null
	Anal and Other Cancer Rates Higher in HIV	done null
	Thalidomide Helps HIV-Related Colitis	done null
	Good Results in Long-Term HCV Treatment Follow-Up	done null
	Latinos Respond Less Well to HCV Treatment	done null
	Gold Nanoparticles Revive HIV Drug’s Prospects	done null
	Monitoring Board Finds HIV Combo Inferior	done null
	Norvir-Boosted Protease Regimen Bests Other Regimens	done null
	Calming the Immune System to Treat HIV	done null

April 2008

Success

null

	Evolutionary Accident Makes HIV Deadly	done null
	Even Failing Treatment Reduces HIV in the Brain	done null
	Bad Teeth Also Bad for Young Men’s Hearts	done null
	High Triglycerides Linked to Fat Abnormalities	done null
	Combined Resistance Analysis Better Predicts Treatment Failures	done null
	Guidelines Panel Leaves Abacavir Recommendations Unchanged	done null
	Hepatitis B Coinfection Doesn’t Affect HIV Treatment	done null
	Hetero Men Also at Risk for Anal HPV	done null
	ADAP Recipients Hit All-Time High in 2007	done null
	Most U.K. Patients Start Treatment Without HIV Resistance Info	done null
	Managing Prostate Cancer No Different in HIV	done null
	Tesamorelin for Lipo: More Data Expected	done null
	Vicriviroc Trial Enrolling Treatment First-Timers	done null
	HIV Immunotherapy Shows Promise	done null
	Tropism Predicts CD4 Loss, Not Treatment Response	done null
	Sexual Dysfunction Linked to Poor Treatment Adherence	done null
	African Americans Have Rapid Kidney Disease Progression	done null
	Insulin Resistance Predicts Heart Disease and Stroke Risk	done null
	CD4s Predictive of Non-AIDS-Related Health Problems	done null
	Treatment Failure: Symptoms Matter Too	done null
	Better Antibiotics for Second-Line PCP Treatment	done null
	HIV Affects Body Shape and Lipids in Women	done null
	Interfering with Immune Protein Slows HIV Reproduction	done null
	Improving the Predictive Ability of a Resistance Test	done null

March 2008

Success

null

	Disalcid Improves Inflammation, But Has Liver Toxicity	done null
	Pneumonia Vaccine Effective in HIV	done null
	HIV-Positive Women Remain Slimmer but Have Higher Waist-to-Hip Ratios	done null
	Neuropathy Pain Patch Fails Test	done null
	Bevirimat Success Hinges on HIV Mutations	done null
	Genetically Reprogrammed Cells Could Battle HIV	done null
	Test for Abacavir Hypersensitivity Works in Black and White Patients	done null
	Fish Oil and Fenofibrate an Effective Combo for High Triglycerides	done null
	Mentally Ill and Substance Users Not Getting Care	done null
	Prezista Warning: Liver Problems Possible	done null
	Race and Gender Impact HIV Treatment Side Effects	done null
	Trust for Doctors High in French Study	done null
	Universal Health Care Doesn’t Ensure Universal HIV Treatment	done null
	Mental Illness and Substance Use Delay HIV Treatment	done null
	Some Genetically Protected Against Lipoatrophy	done null
	Tenofovir Better Tolerated Than Zidovudine for PEP	done null
	PIs Increase Heart Disease Risk, and NNRTIs Decrease It	done null
	Group Psychotherapy Improves Mood, but Not Adherence	done null
	Food Poisoning May Be Fatal for People With HIV	done null
	Charting the Future of Protease Monotherapy	done null
	Lower-Dose Zerit May Improve Some Side Effects	done null
	Some People Not Appropriately Treated for High Cholesterol	done null
	More HIV Cases Reported in 2006	done null
	Genes Predict Immune Response to Antiretroviral Treatment	done null

February 2008

Success

null

	Parasitic Drug Shows HIV-Fighting Promise	done null
	Gilead Loses Key Patents on Tenofovir	done null
	Vicriviroc Shows Well in Treatment-Experienced Patients	done null
	Abacavir, Didanosine Linked to Increased Heart Attack Risk	done null
	Norvir/Reyataz Comparable to Kaletra for First-Line Therapy	done null
	Sexual Reinfection With HCV Following Treatment	done null
	AIDS Survival: Progress Not Perfection	done null
	Once- vs. Twice-Daily Kaletra Tablets: Similar Safety and Potency	done null
	Epzicom Comparable to Truvada as First-Line NRTI Choice	done null
	Male Circumcision Doesn't Reduce Women's HIV Risk	done null
	TDM-Guided PI Dose Increases of Limited Benefit	done null
	Refining HIV Treatment for New Med Takers	done null
	Prevention and Women: HIV-positive and HIV-negative	done null
	Once-Daily Viramune Is at Least as Efficient as Twice-Daily Dosing	done null
	Durable Efficacy Seen in Studies of New NNRTI Intelence	done null
	Nanotechnology May Yield Long-Lasting Meds	done null
	HIV & Your Heart: Part I	done null
	HIV & Your Heart: Part II	done null
	Morris Jackson: Survivor and Treatment Activist	done null
	Prezista Effective and Safe in Positive Kids	done null
	Durable Efficacy and Safety With Isentress Treatment	done null
	Good Bacteria Reduces Vaginal HIV Levels	done null
	New Hope for Treatment Experienced	done null
	Extended-Release Viramune Begins Study	done null
	VIRxSYS Gene Therapy Makes Progress	done null
	Women & HIV Treatment	done null
	World of Prevention: Vaccines and More	done null
	Condom-Free Sex? Controversial Swiss Declaration	done null
	Acyclovir Doesn’t Reduce HIV Infection Risk in HSV-2-Positive People	done null
	Suppressing HIV Improves Kidney Function	done null
	HIV Treatment Improves, but Doesn’t Restore, B Cells	done null
	Starting Treatment With Higher CD4s Cuts Death Rate	done null
	Dipstick Kidney Test Less Accurate in HIV	done null
	Study Links Zerit and Retrovir With Diabetes Risk	done null
	Drug Use Linked to Infection With Resistant Virus	done null
	Discordant Responders Have Faster Disease Progression	done null
	Growth Hormone Boosts Thymus T-Cell Production	done null
	New Prezista 600 mg Tablet Approved	done null
	GeoVax Vaccine to Move Forward	done null
	Safe for Some to Switch to Viramune With Higher CD4 Counts	done null
	Epzicom Efficacy Concerns Lead to ACTG Study Changes	done null
	GSK Comments on ACTG 5202 Study Changes	done null
	HIV Treatment Increases Survival, Not Heart Attack Risk	done null

January 2008

Success

null

	Antiretroviral Therapy Reduces HIV in Lungs	done null
	Peripheral Arterial Disease Risk Found in People With HIV	done null
	FDA Clears Quick Test for Drug-Resistant Staph	done null
	Potential Drug Interaction Between Sustiva and Dilantin	done null
	Antiretrovirals Don’t Increase Heart Disease Risk	done null
	Drug Interaction Caution With Crestor and Kaletra	done null
	Following Treatment Guidelines Generates Best Results	done null
	Hepatitis B Revaccination Effective in People With HIV	done null
	More Heart and Kidney Problems in Treated African Americans	done null
	Recreational Drug Use Had Little Effect on Immune Cells	done null
	Zetia Doesn’t Reduce Artery-Clogging Plaques	done null
	HIV Blocking Proteins Found in Dendritic Cells	done null
	New Multi-Drug-Resistant Staph Infections Plaguing Gay Men	done null
	Low Testosterone Increases Bone-Fracture Risk	done null
	Acid Reflux Meds Allowed With Reyataz	done null
	Low-Dose Interferon Shows Potential for Hep C	done null
	Kaletra Monotherapy Disappoints	done null
	Tibotec’s Intelence (Etravirine, TMC125) is Approved by FDA	done null
	Stigma From Health Care Providers Toward People With HIV	done null
	Antiretrovirals Significantly Increase Survival in HIV-Positive Children	done null
	Antiretrovirals, Cocaine Use Associated With “Silent” Heart Disease	done null
	Swiss Study Finds Less Lipodystrophy in Recent Years	done null
	DHHS Issues Changes to U.S. Treatment Guidelines	done null
	Treatment Interruptions Lower Quality of Life in SMART Trial	done null
	High Rate of Bone Problems in French HIV Patients	done null
	Selzentry May Hold Promise for HIV Prevention	done null

December 2007

Success

null

	Plan to Reduce Late HIV Diagnoses in Europe	done null
	Black MSM Have Higher HIV Rates Despite Similar Risks	done null
	HIV Testing? Not in My ER	done null
	Non-Injection Drug Use Linked to Greater HIV Infection Risk	done null
	Circumcision Not Protective in U.S. Gay/Bisexual Men	done null
	HIV Rates Declining in Some Older Americans	done null
	HIV Rates Increasing Most in Young Black Gay/Bisexual Men	done null
	Sodomy Laws Bad for HIV	done null
	Serious Mental Illness and Addiction in Newly Diagnosed	done null
	Party Drug Use Waning in NYC Gay and Bisexual Men	done null
	Newly Infected People Change Risky Behaviors After Diagnosis	done null
	High Rate of False Positives at DC Clinics	done null
	Are We Ready for PrEP?	done null
	Tesamorelin KO’s Belly Fat	done null
	DHHS Unveils Revised U.S. Treatment Guidelines	done null
	Hep C Treatment Response at Week 4 Predicts Success	done null
	Viread With Boosted PIs Worse for Kidneys	done null
	Viramune Protective Against Hep C Liver Damage	done null
	Triple-Class Drug Failure Uncommon After 10 Years of HAART Use	done null
	Gilead & BMS to Market Atripla in Europe	done null
	HAART Improves Survival With Hodgkin’s Lymphoma	done null
	IVIG Reduces Immune Activation, Boosts CD4 Cells	done null
	Fish Oil Plus Fenofibrate Good for High Triglycerides	done null
	Atripla Approved in Europe	done null
	Drug Holidays Dangerous for Treatment-Experienced	done null
	Trofile Bests SensiTrop as Most Reliable Tropism Test	done null
	Isentress Wins Approval in European Union	done null
	First-Line Therapy Approval Requested for Prezista	done null
	Asymptomatic Ischemia Common in HIV	done null
	Viral Load During Pregnancy: Lower the Better	done null
	HIV-Positive Women Have Higher Risk of Bone Fractures	done null
	Impact of CD4s on HCV Treatment Uncertain	done null

November 2007

Success

null

	Early Treatment Reduces Risk of Three Common Complications	done null
	GSK Discontinues Agenerase Liquid and 50mg Capsules	done null
	Major Lab Company Licenses Tropism Test	done null
	Half of Patients Had AIDS at Time of HIV Diagnosis	done null
	New Guidelines on Treatment of Pregnant Women Released	done null
	New Worries With AIDS Vaccine	done null
	Single-Dose Drug Combination Reduces Non-Nuke Resistance Risk for Moms and Kids	done null
	Immune Reconstitution Inflammatory Syndrome (IRIS) Risk Factors Identified	done null
	People With Kidney Disease Undertreated for HIV	done null
	GSK Sues Abbott Over Norvir Price Hike	done null
	FDA Approves Low-Dose Kaletra for Kids	done null
	Herpes Drug Fights HIV Too	done null
	Suppressing HIV Doesn’t Stop Immune Activation	done null
	High Rate of HIV Superinfection Found in Kenyan Sex Workers	done null
	Metabolic Syndrome Increases Risk for Diabetes and Heart Disease After Starting Treatment	done null
	AIDS Activism Training in Atlanta, December 7 & 8	done null
	Avandia Negatively Affects Cholesterol in HIV-Positive Patients	done null
	Fosamax Safe and Effective for Bone Mineral Loss	done null
	HIV, ARVs Don’t Increase Blood Pressure Risk	done null
	Sculptra Modestly Improves Facial Wasting	done null
	Treating Anal Lesions Nonsurgically	done null

October 2007

Success

null

	Acetyl-L-Carnitine Promising for Neuropathy	done null
	Tesamorelin Promising for Lipodystrophy Over 52 Weeks	done null
	Scientists Discover a Way to Reach Hidden HIV	done null
	Key Protein Blunts Immune System’s Power to Fight HIV	done null
	Needle-Free Fuzeon Abandoned for Now	done null
	Better Quality of Life for People With HIV Who Quit Smoking	done null
	HIV Treatments Protective Against Brain Damage	done null
	Stress May Contribute to HIV Disease Progression	done null
	People on a Failing HIV Regimen May Still See Benefit	done null
	Women Aren’t Talking Treatment With Their Docs	done null
	New Study Finds Alcohol Use and Depression Influence Adherence	done null
	Isentress Gets FDA Approval	done null
	Norvir Dose Lowered for Use With Lexiva	done null
	Rapid Liver Damage Possible in HIV/HCV Patients	done null
	Researchers Recommend Screening for Pulmonary Arterial Hypertension	done null
	Today's Patients Seek HIV Care Later Than Those in 1990	done null
	HIV Increases Risk of Heparin-Induced Thrombocytopenia	done null
	Committee Recommends Approval of Atripla in Europe	done null
	ESRD Nearly Six Times Higher in African Americans With HIV	done null
	Low Body Weight, Not HIV, Linked to Frail Bones	done null
	Kaletra Reduces HIV in the Brain	done null
	Poor Adherence May Explain Worse Sustiva Responses Among Blacks	done null
	Strategies for Success With Kaletra Monotherapy	done null
	More Promising Data on Selzentry for Drug-Resistant HIV	done null
	Aiming Low: 'Undetectable' Not Just for Treatment Newbies	done null
	Safer Family Planning for Positive Couples	done null
	Why Do Those With HIV Have More Heart Attacks?	done null
	Rilpivirine Comparable to Sustiva in Treatment First-Timers	done null
	More Rash With Once-Daily Viramune	done null
	Similar Efficacy, Better Triglycerides with Invirase vs. Kaletra	done null
	Tesamorelin (TH9507) Safe and Effective for 52 Weeks	done null
	Alive and Well: Ten Years of HAART in Advanced HIV Cohort	done null
	Crestor Bests Pravachol for Elevated Lipids	done null
	New Menu of Antiviral Options	done null
	Children and Challenges: Treating Pediatric HIV	done null
	Kaletra Tablets for Children Show Equivalency	done null
	Small Steps Forward in HIV Prevention	done null
	Is Once-Daily Kaletra an Effective Dosing Option?	done null
	Pre-treatment CD4 Count Predicts CD4 Gains on Treatment	done null
	HIV Treatment Greatly Improves Brain Illness Survival	done null

September 2007

Success

null

	Needle-Free Device Improves Life for Fuzeon Users	done null
	Metformin Shows Little Lipodystrophy Benefit in Small Study	done null
	Promising New Nuke, Apricitabine	done null
	Isentress Recommended for FDA Approval	done null
	Study Suggests Treating Hep C Before HIV	done null
	High-Fat Diets Affect Disease Progression	done null
	Pfizer Warns of Cancerous Impurity in Viracept	done null
	HIV Damages Brain Despite Treatment	done null
	Lasting CD4 Increases With IL-2	done null
	More Reports on Kidney Stones With Reyataz	done null
	Pregnancy Protective Against HIV Disease Progression	done null
	Skin Test Predicts Control of HPV	done null
	High Risk of Peripheral Artery Disease in HIV	done null
	Lexiva and Kaletra Comparable in Long-Term Study	done null
	Interview with a Hep C Activist & Survivor	done null
	Heart Disease Risk Remains in Absence of HIV Treatment	done null
	Prezista Shows Well in Patients New to Treatment	done null
	Isentress Offers Long-Term Benefits for Drug-Resistant Patients	done null
	Secrets of a Long-Term Survivor	done null
	Coming Down the Pike: Expanding HIV Treatment Options	done null
	IL-2 May Delay Need for Antiretroviral Treatment	done null
	Elvitegravir Study Highlights Value of Strong Background Regimen	done null
	New Data Explores Current Treatment Options	done null
	Wisdom for Women: An Expert's Take on HIV and Gender Differences	done null
	Selzentry Treatment Failure: The Impact of Tropism Changes	done null
	Two-Year Vicriviroc Benefit in Treatment-Experienced Patients	done null
	FDA Grants Priority Review for New NNRTI, Etravirine	done null
	HIV Prevalence Declines in Pregnant Women in Zimbabwe	done null
	Single-Dose PRO 140 Has Lasting Effects	done null
	48-Week Selzentry Data Show Promise for Drug-Resistant HIV	done null
	Etravirine for NNRTI-Resistant HIV: Pooled DUET Study Results	done null
	Activist Seek Fair Price for Isentress	done null
	Maraviroc Gets EU Approval	done null
	High Rate of Kidney Problems in HIV	done null
	Dry Skin More Common in Positive People	done null
	Genetic Tests Could Help Reduce Sustiva Side Effects	done null
	Ban on European Viracept Sales Lifted	done null
	KP-1461: A New Approach to HIV Treatment Now in Studies	done null
	Past Lexiva Treatment May Reduce Benefit From Prezista	done null

August 2007

Success

null

	Lexiva vs. Reyataz: Comparable Efficacy	done null
	PRO 140 Shows Promise in Single-Dose Study	done null
	Prezista Superior to Kaletra for Treatment-Experienced Patients	done null
	NNRTI Etravirine Effective for Treatment-Experienced Patients	done null
	Pfizer's Selzentry Gets FDA Approval	done null
	Women Do Better on Tipranavir/Ritonavir	done null
	Europe Suspends Viracept Sales	done null
	Non-AIDS Cancer Risk Higher for People with HIV	done null
	HPV Vaccination For All Positive Gay Men?	done null
	Nukes, not PIs, Tied to Diabetes in Positive Women	done null
	High CD4s No Guarantee against AIDS and Death	done null
	Infant Dies of Kaletra Overdose, Prompts Warning	done null
	New Infection Symptoms Affect Viral Load, Speed to AIDS	done null
	Good Treatment Results for Over 50s	done null
	Higher Risk of C-Section Complications in Positive Women	done null
	Cost Shouldn’t Be Obstacle to Lipo Treatment	done null
	HIV’s Two-Pronged Attack on the Brain	done null
	Kidney Problems Require Careful NRTI Dosing	done null
	Scientists Say Internet Gives AIDS Denialists New Life	done null
	New Blood Test for PCP Holds Promise	done null
	Put All Your Pills in One Basket	done null
	Fat Buildup Increases Insulin Resistance Risk	done null
	Are Viral Load 'Blips' Really Harmless?	done null
	Marijuana or Marinol? Both Show Benefits	done null
	Nukes, Not PIs, Linked to Diabetes Risk	done null
	Memantine May Help Prevent, Not Treat, Dementia	done null
	Zero Infections in Large Sperm Washing Study	done null
	Pneumococcal Vaccine Effective in Positive People	done null

July 2007

Success

null

	HIV Treatment Increases Risk of Diabetes	done null
	Children's Sustiva Dose May Need to be Upped	done null
	Prezista/Norvir Bests Kaletra in Treatment-Experienced Patients	done null
	Dynamic Duo Etravirine and Prezista Shine in Studies	done null
	HIV Increases Lung Cancer Risk	done null
	Zetia Helps Lower Lipid Lipids in HIV	done null
	New Method Identifies Rare Resistance Mutations	done null
	HIV Treatment Boosts Birth Rate	done null
	Despite Flu Shot, Flu Often Occurs in HIV	done null
	Treatment Access Isn't Just a Global Issue	done null
	No Lipodystrophy Approval for Serostim	done null
	Tenofovir's Long-Term Safety Profile	done null
	Celsentri (Maraviroc) Interaction Warning	done null
	AIDS Down Under: IAS Conference Begins in Sydney	done null
	Fauci Defends Bush's AIDS Legacy	done null
	Crystal Meth Linked to Lower CD4s in Positive People	done null
	Timed Intercourse Plus PrEP for Low-Risk Natural Conception	done null
	An Eccentric Professor Expounds on Growing Old With HIV	done null
	Are We Starting Treatment Early Enough?	done null
	Merck’s Isentress Comparable to Sustiva as a First-Time Treatment	done null
	HIV Infection Linked to Higher Skin Cancer Risk	done null
	Rilpivirine (TMC-278) Has Metabolic Edge Over Sustiva	done null
	Vicriviroc Shows Benefits, Continues Development	done null
	A Positive Papua New Guinean Speaks Out Against Stigma	done null
	The Latest on Lipo: Advances & Setbacks	done null
	Which HIV Meds Cause Lipoatrophy?	done null
	Sustiva Edges Out Celsentri in Treatment Newbies	done null
	Simple Test Can Help Prevent Abacavir Allergy	done null
	High Risk of Kidney Problems in HIV	done null
	Pipeline Preview: All The New AIDS Drugs Coming Soon	done null
	Simple Test Eliminates Abacavir Risk	done null
	Norvir/Invirase Go Head-to-Head with Kaletra	done null
	Starting or Switching: Truvada Outpaces Combivir in Studies	done null
	Is HIV Treatment Actually Reducing Heart Attack Risk?	done null
	Beyond Condoms: Medical Approaches For Prevention	done null

June 2007

Success

null

	Early Treatment may have CD4 Advantage	done null
	New Drugs Possible from Discovered HIV Transport System	done null
	Roche's Viracept Recalled; Pfizer's U.S. Version Okay	done null
	People with HIV May Need Longer TB Treatment	done null
	LDL Drops with Sustiva to Viramune Switch	done null
	Twins Pregnancy Carries Greater HIV Risk	done null
	Non-Nuke Shows Early Promise as Microbicide	done null
	Racially and Gender Diverse Aptivus Study Underway	done null
	Several Factors Raise Women's Bone Loss Risk	done null
	Reyataz May Cause Kidney Stones	done null
	Death Rates Higher Among Rural Positive Patients - But Why?	done null
	Maraviroc: Approvable, but not yet Approved	done null
	Hep B and HIV Baraclude Users Beware	done null
	Panacos' Bevirimat Back on Track	done null
	Drug-Resistant HIV in Semen Stirs Concerns	done null
	Dietary Supplement Rule Announced, Questioned	done null
	Treatment Improves Survival Among IDUs	done null
	Neuro Problems may Persist with Treatment	done null
	HIV, PIs Don't Lead to Artery Thickening	done null
	Designer Enzyme to Fight HIV Shows Promise	done null
	Polyalkylimide Injections Improve HIV Lipoatrophy	done null
	Children with HIV Face Increased Heart Disease Risk	done null

May 2007

Success

null

	PRO 140 Has Potent and Lasting HIV Effect	done null
	Race, Mental Health Affect HIV Treatment	done null
	HAART to Heart: It’s Not Just the Meds	done null
	Possible Lipo Drug Dropkicks Glucose	done null
	HIV Treatment Good for Growth in Kids	done null
	Uncommon Causes of Stroke More Frequent in HIV	done null
	Green Tea for HIV Dementia	done null
	Glitazones Not Likely Useful for Lipoatrophy	done null
	Study Explores Lipid Problems in Women	done null
	Hysterectomy Rates Higher in Women with HIV	done null
	PIs and Non-Nukes Cause Similar Metabolic Problems	done null
	No Drop in Non-AIDS Cancer Rates	done null
	Kaletra Regimens 'Forgiving' of Missed Doses	done null
	Study Finds Abacavir Allergy Screening Useful	done null
	Pubic Lipomas a Lipo Symptom?	done null
	Regular Healthcare Visits a Key to Survival	done null
	HIV Vaccines May Work in Unexpected Ways	done null
	Accurate Immune System Marker in Poor Countries	done null
	Spinal Chemicals May Predict HIV Dementia Risk	done null
	'Runaway' Theory Doesn't Explain Slow CD4 Loss	done null
	Some Do Well After Treatment Interruption	done null
	'Serosorting' Risk can be High	done null
	Lipid Problems Explored in Women	done null

April 2007

Success

null

	GSK Reports Combivir and Ziagen Tampering	done null
	Large Study Links Meth Use and HIV Risk	done null
	48-Week Prezista Data Published	done null
	Home HIV Test in the Works	done null
	Rabies: An HIV Therapy?	done null
	571 on ADAP Waiting Lists	done null
	Natural Molecule in Blood Blocks HIV	done null
	First CCR5 Blocker Gets Vote of Approval	done null

March 2007

Success

null

	Once-Daily Viramune Strikes Out	done null
	Fewer Side Effects with Videx/Epivir vs. Combivir	done null
	Integrase Inhibitor Elvitegravir (GS-9137) Shows Well	done null
	Non-Nuke TMC-278 Comparable to Sustiva	done null
	HIV+ Less Responsive to Lipid-Lowering Meds	done null
	Study Says Less Fat for Lower Lipids	done null
	Baraclude Induces HIV Drug Resistance	done null
	Still No Clear Benefit of Treating Early HIV	done null
	Twice-Daily Kaletra Possibly Better for Some Patients	done null
	Study Finds Viread Advantages in Black Patients	done null
	Mental Illness Affects HIV Treatment Responses	done null
	Black HIV/AIDS Rates Disproportionately High	done null
	Testosterone Doesn't Build Muscle in Wasting	done null
	Early HCV Response Predicts Outcome	done null
	Sharp Drop in Hepatitis Cases	done null
	Apricitabine Useful for Drug-Resistant HIV	done null
	Less Lipo and Better Lipids with Ziagen vs. Zerit	done null
	Poz Kids Can Maintain Stable CD4s	done null
	HPV Vaccine May Slow HIV	done null
	Counseling Can Reduce HIV Spread	done null
	Fish Oil Lowers Lipids in HIV	done null
	WHO & UNAIDS: Male Circumcision Recommended to Slow HIV Spread	done null
	Green Tea for HIV?	done null

February 2007

Success

CMS encountered an error while attempting to publish this article

click here To Try Again

	Asthma Med for IRIS?	done null
	Despite Setback, Advocates Push for Continued Microbicide Research	failed null
	Hep C: Heavy Drinking Riskier for Women than Men	done null
	HIV Rates Drop Among Florida Blacks	done null
	GSK Offers $50 Savings Card to Lexiva Users	done null
	IL-7 May Protect CD4 Cells in HIV	done null
	PN Study Supports Medical Marijuana	done null
	Metabolic Syndrome No More Common in HIV	done null
	Herpes Raises Pregnancy Transmission Risk	done null
	Protein Discovery May Aid Vaccine Development	done null
	Prezista Receives European Approval	done null
	Disclosure May Boost CD4 Counts	done null
	Are We Spending Too Much on HIV?	done null
	HIV Protein to Fight Cancer	done null
	Low Risk of Premature Births with HIV Treatment	done null
	Fosamax, Calcium, and Vitamin D for Bone Weakness	done null
	Zetia Lowers 'Bad' LDL Cholesterol	done null
	More Lipoatrophy with Sustiva vs. Kaletra	done null
	Double-dose Viread effective against NRTI-resistant HIV	done null
	One in 10 Infected with Drug-Resistant HIV	done null
	TH9507 Shows Promise for Lipodystrophy	done null
	Breastfeeding Safer for Some HIV+ Mothers	done null
	Isentress (MK-0518) Results Prove Promising	done null
	Encouraging Data from Two Maraviroc Studies	done null
	Shift in Cancer-Related Deaths in HIV	done null

January 2007

Success

null

	Risk of HIV Shedding Greater With NNRTIs Than PIs	done null
	Abacavir in Kids with HIV-Associated Encephalopathy	done null
	WSJ Uncovers Abbott's Norvir-Busting Marketing Strategies	done null
	A More Sensitive Drug Resistance Test	done null
	High HIV Lung Cancer Risk (Not Just From Smoking)	done null
	Early Treatment Linked to CD4 Gains	done null
	Nevirapine Works After Use in Pregnancy	done null
	'Serosorting' Appears To Be Limiting Spread of HIV	done null
	AIDS Dementia Predicts Time to Death	done null
	Lifespan Expanding for Patients with HIV	done null
	Risk of BCG Infection in Positive Infants	done null
	Selenium Treatment Beneficial in HIV	done null
	PIs Increase Carotid Thickness in Women	done null
	Hundred-Fold Greater Risk of Osteonecrosis in HIV	done null
	Leishmaniasis Drug Stimulates HIV Replication	done null
	After the Hype, Depakote no Cure for HIV	done null

December 2006

Success

null

	Routine Testing Is Cost Effective	done null
	Lipolytic-Blocker Improves Metabolic Profile	done null
	CD4s in Gut Respond Poorly to Treatment	done null
	Gel Condom to Prevent HIV	done null
	Drug Combo for High Cholesterol	done null
	HIV and Treatment Raise Risk of Bone Weakness	done null
	Many Factors in Treatment Hepatotoxicity	done null
	Long-Term Data on Combivir vs. Viread/Emtriva	done null
	Early Therapy for HIV/HCV Coinfected	done null
	GSK Halts PI Brecanavir	done null
	Cotrimoxazole Improves Pregnancy Outcomes	done null
	High Rates of Drug Resistance Among Teens	done null
	Good News for HIV Positive Surgical Patients	done null
	TH9507 Causes Modest Fat Drop in Lipo Study	done null
	Maturation Inhibitor Bevirimat Hits Dosing Snag	done null
	HAART Tied to Hodgkin's Lymphoma	done null
	NNRTIs May Have Edge in HIV Therapy	done null
	Gag Reflex: HIV Protein Should Be Vaccine Target	done null
	Radiesse Approved for HIV Lipoatrophy	done null
	Immunotherapy May Enhance HIV Therapy	done null
	HIV Suppressed More in CSF Than Plasma	done null

November 2006

Success

null

	HIV Infects Epithelial And Brain Cells Lacking CD4	done null
	HIV Treatment: That'll be $618,900, Please	done null
	Making (Anti)sense of Gene Therapy	done null
	Indian Alert on Faulty HIV Tests	done null
	New U.S. HIV Cases Cost $12 Billion a Year	done null
	Once-daily lopinavir/ritonavir effective in HIV	done null
	Monoclonal Gammopathy in People With HIV	done null
	Making Babies the Old-Fashioned Way	done null
	Gene Therapy for HIV Infection Shows Promise	done null
	Success With Radioactive Antibody Therapy	done null
	Zinc Supplements Don't Improve Diarrhea	done null
	Boosted Invirase vs. Kaletra	done null
	Vaginal Infections Decline	done null
	Innate Factors May Block HIV in Women	done null
	Radiolabeled Antibodies Kill HIV-1-Infected Cells	done null
	Treatment Interruption No Benefit to Multidrug Resistant	done null
	Belly Fat Gains no More Common in HIV	done null
	Imiquimod for Anal Intraepithelial Neoplasia?	done null
	HIV Infection On The Rise Worldwide	done null
	Adding Enfuvirtide Doesn't Help	done null
	Treatment Adherence Depends on Many Factors	done null
	Gorilla Virus Source of Some HIV Infections	done null
	Psychiatric Disorders Make HIV Treatment Costly	done null
	Micronutrient Deficiency Rare in Treated Patients	done null
	World AIDS Day Report: "Millions of Lives at Risk"	done null
	Not So SMART: Interruption Strategy Questioned	done null
	COPD More Likely in Patients With HIV	done null
	Thymidine-Sparing Regimen Improves Lipoatrophy	done null

October 2006

Success

null

	ICAAC: Norvir-Boosted Lexiva vs. Reyataz	done null
	ICAAC: Trizivir vs. Reyataz/Combivir	done null
	Diet and Exercise Fight Metabolic Syndrome	done null
	Tenofovir Prodrug Delays SHIV Infection	done null
	AIDS Activist With Baboon Marrow Transplant Dies	done null
	Bacteria Protein Prevents HIV Entry	done null
	Course Of HIV Neurologic Disease Variable, Related To Platelet Count	done null
	Animal Study Indicates Alcohol May Accelerate HIV Progression	done null
	AIDS activist with baboon marrow transplant dies	done null
	Enfuvirtide As Rescue Therapy in Med-Experienced	done null
	Enfuvirtide As Rescue Therapy	done null
	Tyzeka Approved for Hepatitis B	done null
	Vulnerable HIV Patients Less Likely To Have Care	done null
	Vaccine Series Safe In Children	done null
	Medecins Sans Frontieres Founder Wants Stronger WHO	done null
	Boosted Atazanavir Of Mixed Benefit In Pediatric HIV	done null
	Progression-Free Survival Common For Pregnant Women	done null
	New Treatment Guidelines for HIV-Positive Children	done null

September 2006

Success

null

	Greater Risk of Bone Loss in HIV-Positive Women	done null
	Standard Dosage Works for Overweight	done null
	EAP Launched for First Integrase Inhibitor	done null
	Treating Primary HIV Infection: Is There a Benefit?	done null
	CDC Recommends Routine HIV Testing	done null
	Smokers May Be at Greater Risk of HIV Infection	done null
	ICAAC: MK-0518 Appears Lipid Friendly	done null
	ICAAC: Abortion Pill for HIV? Questions Still Remain	done null
	Prezista Women's Study Opens for Enrollment	done null
	ICAAC: Predicting Responses to Aptivus or Prezista	done null
	ICAAC: MK-0518 Potent for Treatment Experienced	done null
	ICAAC: More Drug-Resistant HIV?	done null
	ICAAC: Prezista and Aptivus on Drug-Resistant HIV	done null
	Predictive Value of Viral Load Testing Questioned	done null

August 2006

Success

null

	New Genetic Test Ready for Prime Time?	done null
	HIV Hides from Treatment in the Gut	done null
	Dosing Questions May Slow TNX-355 Development	done null
	Lipodystrophy in Women: More Data from FRAM	done null
	IAC: Serostim As Immune-Based Therapy?	done null
	IAC: Four Drugs Vs. Three	done null
	IAC: Encouraging Data on Etravirine (TMC-125)	done null
	IAC: 48-Week Prezista POWER Results Presented	done null
	IAC: Tibotec VP Discusses Latest On Prezista	done null
	IAC: Markowitz on the Supervirus Case	done null
	IAC: Nutritional Boost CD4 Counts	done null
	IAC: Meds Improve Growth and Body Composition	done null
	IAC: Fauci Gets Grilled	done null
	IAC: Activist Gonsalves Slams Gates & Clinton	done null
	IAC: Challenges of Reaching Countries in Need	done null
	IAC: Lexiva Measures Up to Kaletra	done null
	IAC: Maraviroc Less Effective but Safe for Some	done null
	IAC: Vicriviroc Shows Promise	done null
	IAC: Data, Access for Integrase Inhibitor	done null
	IAC: Encouraging TNX-355 Data	done null
	IAC: Growth Hormone for Lipo	done null
	IAC: Lead Researcher Discusses KLEAN	done null
	IAC: Markowitz on MK-0518	done null
	IAC: Kotler Responds to Critics of FRAM	done null
	IAC: Sustiva vs. Kaletra? We Have a Likely Winner	done null
	IAC: Is Kaletra Monotherapy Possible?	done null
	T-Cell Protein May Be HIV Treatment Opportunity	done null
	Topical Version of Protease Inhibitor May Treat HPV	done null
	Second Facial Filler for HIV Lipoatrophy Receives Approval Recommendation	done null

July 2006

Success

null

	New Aptivus Warning: Bleeding in the Brain	done null
	One-Pill, Once-Daily Combo Approved	done null
	Doctors, Patients Disagree on Resistance Concerns	done null
	Study Confirms Treatment Benefit for Children	done null
	I Forgot	done null
	An HIV Drug Says Goodbye	done null
	Pregnancy Treatment Guidelines Revised	done null

June 2006

Success

null

	Making the Link: Chimps Believed Source of HIV	done null
	Got Milk? Don't Let Dairy Get You Down	done null
	Aptivus Study Halted	done null
	HIV Vaccines: They're Not Perfect But...	done null
	HIV's Wicked Ways: An Accident of Evolution?	done null
	Protease Inhibitor Prezista Approved	done null
	Activists Say New HIV Drug Price Encouraging	done null
	HIV/AIDS Treatment: Three Million Years of Life Saved in U.S.	done null

May 2006

Success

null

	Updated Treatment Guidelines Published	done null
	Survey: HIV Docs and Patients Don't Always See Eye-to-Eye	done null
	Lexiva vs. Kaletra	done null
	Entry Inhibitor TNX-355: New Phase 2 Study Data	done null
	Covering Our Asses: A Healthcare Provider Questions CDC HPV Information	done null
	HPV Vaccine Receives Approval Recommendation	done null

April 2006

Success

null

	Truvada and HIV Prevention: The Hope Behind the Hype	done null
	Big Expectations for Gene Therapy	done null
	Development of NRTI Reverset Halted	done null

February 2006

Success

null

	Preventing HIV Transmission with Tenofovir + Emtricitabine	done null
	Investigating Reports of Excessive False-Positive Oral Fluid Rapid HIV Tests	done null
	Trends in HIV Diagnosis among Non-Hispanic Blacks	done null
	SMART and Treatment Interruptions: The Results Are In	done null

May 2009

Success

null

	Transcript: Antiretroviral Highlights from CROI	done null
	Transcript: HIV and Women	done null
	Transcript: HIV and the Brain	done null
	Transcript: HIV and Cancer - Prevalence and Prevention	done null

April 2009

Success

null

	Transcript: Prevention Highlights Part 1- PrEP	done null
	Transcript: Prevention Highlights Part 2 - Treatment as Prevention	done null

March 2009

Success

null

HIV and Women

done

null

February 2009

Success

null

	Coming Soon	done null
	Diabetes Drug Avandia Helps Reverse Lipoatrophy	done null
	GS 9350 and SPI-452: Emerging Alternatives to Norvir Boosting	done null
	HIV Treatment Greatly Reduces, But Doesn’t Eliminate Transmission	done null
	Kaletra-to-Isentress Switch Helps Lipids, but With Viral Rebound Risk	done null
	Start HIV Treatment Early—But When?	done null
	IL-2 Fails in Two Large Studies	done null
	Age, Diabetes & a Bigger Waist Line Tied to Cognitive Problems in HIV	done null
	PIs, Abacavir and Cardiovascular Disease: What’s the Risk?	done null
	D:A:D Study: Reduce Modifiable Risk Factors to Improve Survival	done null
	HIV Itself Is a Major Heart Disease Risk Factor	done null
	Isentress Shows Long-Term Benefits in Treatment-Experienced Patients	done null
	First Data From Injectable PRO 140 Study	done null
	Antidepressants Improve Viral Load Response to Treatment Due to Better Adherence	done null
	Microbicides Make a Comeback	done null
	Smoking Cessation: Hispanics, Nicotine Patch Users Do Best	done null
	Nerve Damage Is a Common Problem in People With HIV	done null
	HDL and Small HDL Particles Predict Cardio Problems in HIV	done null
	Scientists Still Seeking Clues to Abacavir Heart Attack Mystery	done null
	Quarter of U.S. Positive Women Not Receiving Annual Pap Smears	done null
	Aging and HIV a Destructive Combination on the Brain	done null
	Antiretroviral Highlights from CROI	done null
	Testosterone Therapy: Good for Women Too	done null
	Lymphoma: Death Rates Still High, but Cancer May Be Predicted	done null
	Sexually Transmitted Hepatitis C in MSM in the U.S. and Europe	done null
	Half of Deaths in People With HIV No Longer From AIDS	done null
	HIV and Cancer: Prevalence and Prevention	done null
	HIV and the Brain: What to Watch Out For	done null
	Prevention Highlights, Part 1: PrEP	done null
	Prevention Highlights, Part 2: Treatment as Prevention	done null

November 2008

Success

null

	Truvada vs. Epzicom: The Debate Goes On	done null
	Drug-Resistant Staph: Growing Concern Among People With HIV	done null
	High Number of Pulmonary Hypertension Cases in Naval HIV Cohort Study	done null
	Drug-Resistant Staph and HIV - Part 1	done null
	Drug-Resistant Staph and HIV - Part 2	done null
	HIV News at ICAAC/IDSA - Part 1	done null
	HIV News at ICAAC/IDSA - Part 2	done null

October 2008

Success

null

	Isentress Comparable to Sustiva for First-Time Treatment	done null
	Selzentry Reanalysis Shows Potential as First-Line Treatment	done null
	Should ARV Treatment Be Started When CD4s Fall Below 500?	done null
	PRO 140 Has Long-Lasting Activity Against HIV	done null
	Greater HIV Response to Prezista vs. Kaletra for First-Timers Over 96 Weeks	done null
	New NNRTI Called RDEA806 Shows Promise	done null
	Higher Response Rate with Norvir-Boosted Reyataz vs. Kaletra as First-Line Therapy	done null
	Has HIV Evolved to Become More Dangerous?	done null
	Long-Term Benefits and Risks of Kaletra Monotherapy Explored in Two Studies	done null

IAC 2008

Success

null

	Similar Survival Among IDUs on ARV Treatment	done null
	Human Rights Struggles Define AIDS Fight	done null
	IAC Panelists: Scale Up, Leadership and Youth Crucial to HIV Response	done null
	Future Options for the Treatment Experienced	in progress null
	Vaccines: Lessons Learned	waiting null
	Abacavir and Heart Attack Risk: Round 2	waiting null
	Achieving Universal Treatment Access: The Experience in Rural Malawi	waiting null
	Defining the Risk Factors for Kidney Damage in Patients Using Tenofovir	waiting null
	Sustiva Bests Kaletra for Treatment of Advanced HIV Disease	waiting null
	Microbicides: Assessing Progress	waiting null
	IDX899 Safe, Reduces Viral Load in Preliminary Study	waiting null
	New Options for Those New to Treatment	waiting null
	New HIV Numbers: New Prevention Strategy? Part 2	waiting null
	AIDS Activism For The Next Decade	waiting null
	Hep C: The Other Epidemic	waiting null
	Some Gender and Racial Differences with Three Protease Inhibitors	waiting null
	PrEP: Preparing For Success?	waiting null
	NNRTI Rilpivirine (TMC-278) Comparable to Sustiva in 96-Week Study	waiting null
	Encouraging Data From Second Tesamorelin Study for Lipo	waiting null
	New HIV Numbers: New Prevention Strategy? Part 1	waiting null
	Shortage of Health Care Workers Threatens African HIV Care	waiting null
	New NNRTI RDEA806 Shows Promise in Seven-Day Study	waiting null
	Transcript: AIDS Activism For The Next Decade	waiting null
	Transcript: Vaccines, Lessons Learned	waiting null
	Studies Disagree on Abacavir for Patients With High Viral Loads	waiting null
	Abacavir and Cardiovascular Risk: Is There or Isn’t There?	waiting null
	Isentress, Intelence and Prezista Combo Shines for Treatment Veterans	waiting null
	Transcript: Human Rights Struggles Define AIDS Fight	waiting null
	Having Children a Priority for Many Positive Women	waiting null
	Milk Thistle Shows Potential for Hep C	waiting null
	Transcript: Future Options for the Treatment Experienced	waiting null
	Stigma, Fear of Side Effects, Keep Many off Treatment	waiting null
	Report: Now Is Time to Prepare for PrEP	waiting null
	Norvir Tablets Similar to Capsules, Expected in 2009	waiting null
	Transcript: PrEP - Preparing for Success?	waiting null
	Annual HIV Infections in U.S. Substantially Higher Than Believed	waiting null
	Isentress Continues to Show Well Versus Sustiva as First-Line Treatment	waiting null

CROI 2008

waiting

null

December 2007

waiting

null

November 2007

waiting

null

October 2007

waiting

null

October 2007

waiting

null

September 2007

waiting

null

June 2009

waiting

null

May 2009

waiting

null

April 2009

waiting

null

March 2009

waiting

null

February 2009

waiting

null

January 2009

waiting

null

December 2008

waiting

null

November 2008

waiting

null

October 2008

waiting

null

September 2008

waiting

null

August 2008

waiting

null

July 2008

waiting

null

June 2008

waiting

null

May 2008

waiting

null

April 2008

waiting

null

March 2008

waiting

null

February 2008

waiting

null

January 2008

waiting

null

December 2007

waiting

null

November 2007

waiting

null

October 2007

waiting

null

September 2007

waiting

null

August 2007

waiting

null

July 2007

waiting

null

October 2007

waiting

null

August 2007

waiting

null

July 2007

waiting

null

CROI 2007

waiting

null

October 2005

waiting

null

» »

XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008

Future Options for the Treatment Experienced

August 12, 2008

At the XVII International AIDS Conference in Mexico City, David Evans talks with Andrew Carr, MD, Professor of Medicine at the University of New South Wales in Sydney, Australia, who shares his views on the future of HIV treatment and what's in the pipeline for people with HIV who've been on many treatment regimens.

9 1/4 minutes. Click here to view the transcript.

Scroll down to comment on this story.

Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.

Previous Comments:

comments 1 - 1 (of 1 total)

mark, , 2008-08-13 12:48:10
the transcript is so much more important...

comments 1 - 1 (of 1 total)

Our general International AIDS Conference coverage is made possible with a charitable grant from Bristol-Myers Squibb.